Our offering
Our offerings are designed around one goal: Improving the success of your viral vector project
End-to-end solutions from R&D to commercial manufacturing
Excellence in genome optimization
- Our experts optimize the entire cassette, including the gene of interest, the regulatory elements, and others, e.g., to improve expression
- We also check your genomic sequence for potential IP conflicts if requested
Capsid optimization and immune response regulation*
- We work with established partners who are dedicated to capsid optimization, including AI approaches
- We are establishing a proprietary partnership with a Swiss-based company to remove AAV antibodies from the blood (in piloting phase)
*Expanding our current offerings
Strong experience in scale-up
- We work with GMP grade materials early on in the process to avoid changes when scaling up
- Our infrastructure is harmonized across different scales in USP and DSP
Highly reliable production and GMP services*
- Our GMP team has extensive experience from clinical to commercial scale manufacturing
- The brand new cGMP facility in Zurich, CH, offers the full flow from cell to vial all out of one location
*Expanding current offering
Full spectrum, advanced analytical services
- Our cutting-edge analytics and bio-informatics platform is in-house, allowing for short cycle times
- Dedicated experts help you define your analytics strategy with long-term success in mind
Global network services
- DINAMIQS benefits from Siegfried’s global footprint, with 13 sites across US, Europe, and China. We have full access to Siegfried’s sterile drug products manufacturing network in US and Europe
- We build on a network of unrivalled expertise, e.g., more than 30 regulatory experts
Client service philosophy
- We will not force you into a predefined blueprint but provide flexibility in the process design
- We invest in our people, so that you don’t have to face changing project teams all the time
Our facilities
Located in Schlieren-Zurich Bio-Technopark, Switzerland, our facilities include a fully operational, 13,000-square-foot state-of-the-art R&D facility dedicated to process development, manufacturing up to 50 liter scale and analytical testing. DINAMIQS is currently building a 26,000-square-foot GMP facility that can produce viral vectors at 500 liter scale.